.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH04_Naloxone.Naloxone .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH04_Naloxone.Naloxone| name: | Naloxone |
| ATC code: | A06AH04 | route: | intravenous |
| n-compartments | 2 |
Naloxone is an opioid antagonist used primarily to rapidly reverse opioid overdose. It binds to opioid receptors and can reverse and block the effects of other opioids, including respiratory depression, sedation, and hypotension. Naloxone is approved and widely used today both in emergency settings and by bystanders.
Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.
Saari, TI, et al., & Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clinical pharmacokinetics 63(4) 397–422. DOI:10.1007/s40262-024-01355-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38485851
Dowling, J, et al., & Graudins, A (2008). Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Therapeutic drug monitoring 30(4) 490–496. DOI:10.1097/FTD.0b013e3181816214 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18641540
Robinson, A, & Wermeling, DP (2014). Intranasal naloxone administration for treatment of opioid overdose. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 71(24) 2129–2135. DOI:10.2146/ajhp130798 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25465584